. 2019 May 22;86(6):676–686. doi: 10.1016/j.bjorl.2019.04.008

Table 5.

Univariate analysis for local recurrence-free survival, regional recurrence-free survival and distant metastasis-free survival.

		LRFS			RRFS			DMFS
		HR	95% CI	p	HR	95% CI	p	HR	95% CI	p
Gender	Female	1.19	0.787–1.824	0.39	1.57	0.789–3.157	0.19	1.11	0.680–1.839	0.66
Gender	Male
Age	≤50	1.39	0.589–3.310	0.44	0.83	0.417–1.667	0.60	1.04	0.396–2.741	0.93
Age	>50
T category	T 1–2	0.90	0.596–1.378	0.64	0.86	0.424–1.777	0.69	1.06	0.661–1.713	0.79
T category	T 3–4
N category	N 0–1	1.24	0.814–1.905	0.31	1.00	0.501–2.005	0.99	1.06	0.661–1.713	0.79
N category	N 2–3
RT technic	3D-RT	0.23	0.068–0.787	0.01	21.6	0.0–5.223	0.68	0.35	0.80–1.540	0.16
RT technic	IMRT
TNM stage	II	1.00	0.552–1.837	0.92	1.63	0.601–4.428	0.61	1.53	0.765–3.095	0.45
	III
	IVA
Chemotherapy	Weekly	0.46	0.156–1.366	1.62	0.26	0.033–2.171	0.21	1.17	0.430–32.33	0.74
Chemotherapy	3 weekly
Cumulative dose	≥200 mg/m²	0.42	0.175–1.050	0.06	0.55	0.111–2.746	0.46	0.66	0.217–2.044	0.47
Cumulative dose	<200 mg/m²

3D-RT, three-dimensional radiotherapy; IMRT, intensity modulated radiotherapy; TNM, T and N categories are according to 8th edition American Joint Commission on Cancer staging system.